Grupo Nutresa: Moderate growth in 2Q14 as a result of the adoption of Sicad II rate in Venezuela's operations
August 5, 2014 (www.investorideas.com newswire) 2Q14 results were neutral-negative given the impact of VEF devaluation on international sales. Quarterly results were characterized by a slowdown in Revenues, EBITDA and Net Income growth vs 1Q14 figures. As VEF devaluation will impact financial results from now on given that the company should convert Venezuela's revenues at Sicad II instead of Cencoex, we decided to put our Target Price under review. We highlight the sustained profitability throughout the year (13,9%) given the company's hedging policy and the improvement in the mix of products sold, as well as the good performance of TMLUC profitability during the quarter.
To View Complete Report: Grupo Nutresa
Corredores Asociados S.A. Comisionista de Bolsa is not responsible for investment decisions that may be derived from the information and analyses presented in this document. These decisions, their effects and consequences will be the sole responsibility of the investor. The information published is informative and has been taken from reliable sources, but Corredores Asociados S.A. does not guarantee that they are free of errors. Total or partial reproduction of this document is not allowed without the prior and express authorization of Corredores Asociados S.A.
This news is published on the Investorideas.com Newswire and its syndicated partner network
Get free news alerts:
Sign up here
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.